A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
Clinical trial NCT04626297 · COMPLETED
Trial details
- NCT number
- NCT04626297
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-17
- Primary completion
- 2022-08-03
- Enrollment
- 254
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.